Anavex Life Sciences Corporation logo

AVXL

Anavex Life Sciences Corporation

$10.96

Earnings Summary

Revenue
$0Mn
Net Profits
$-10.44Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Anavex Life Sciences Corporation’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Anavex Life Sciences Corporation has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Anavex Life Sciences Corporation’s net profit fell -27.99% since last year same period to $-10.44Mn in the Q1 2022. On a quarterly growth basis, Anavex Life Sciences Corporation has generated 4.09% jump in its net profits since last 3-months.

Net Profit Margins:

Anavex Life Sciences Corporation’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Anavex Life Sciences Corporation has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Anavex Life Sciences Corporation post its latest quarter earnings

EPS Estimate Current Quarter
-0.15
EPS Estimate Current Year
-0.15

Highlights

EPS Estimate Current Quarter:

Anavex Life Sciences Corporation’s earning per share (EPS) estimates for the current quarter stand at -0.15 - a 11.76% jump from last quarter’s estimates.

EPS Estimate Current Year:

Anavex Life Sciences Corporation’s earning per share (EPS) estimates for the current year stand at -0.15.

Key Ratios

Key ratios of the Anavex Life Sciences Corporation post its Q1 2022 earnings

Earning Per Share (EPS)
-0.14
Return on Assets (ROA)
-0.17
Return on Equity (ROE)
-0.3
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Anavex Life Sciences Corporation’s earning per share (EPS) fell -16.67% since last year same period to -0.14 in the Q1 2022. This indicates that the Anavex Life Sciences Corporation has generated -16.67% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Anavex Life Sciences Corporation’s return on assets (ROA) stands at -0.17.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Anavex Life Sciences Corporation’s return on equity (ROE) stands at -0.3.

Dividend Per Share (DPS):

Anavex Life Sciences Corporation declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-10
-0.17
-0.14
17.65%

Company Information

Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), recently completed a successful Phase 2a clinical trial for Alzheimer's disease. ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 (blarcamesine) also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 (blarcamesine) for the treatment of Parkinson's disease. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising preclinical drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation.

Organisation
Anavex Life Sciences Corporation
Headquarters
New York, New York, US
Employees
20
Industry
Health Technology
CEO
Christopher Missling